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Abstract
The TLX1 transcription factor oncogene plays an important role in the pathogenesis of T-cell acute 
lymphoblastic leukemia (T-ALL). However, the specific mechanisms of T-cell transformation 
downstream of TLX1 remain to be elucidated. Here we show that forced expression of TLX1 in 
transgenic mice induces T-ALL tumors with frequent deletions and mutations in Bcl11b, and 
identify the presence of recurrent mutations and deletions in BCL11B in 16% of human T-ALLs. 
Most notably, mouse TLX1 tumors were typically aneuploid and showed a marked defect in the 
activation of the mitotic checkpoint. Mechanistically, TLX1 directly downregulates the expression 
of CHEK1 and additional mitotic control genes and induces loss of the mitotic checkpoint in non 
transformed preleukemic thymocytes. These results identify a novel mechanism contributing to 
chromosomal missegregation and aneuploidy active at the earliest stages of tumor development in 
the pathogenesis of cancer.
T-ALL is an aggressive hematologic tumor resulting from the malignant transformation of 
T-cell progenitors. The TLX1 transcription factor oncogene is translocated and aberrantly 
expressed in 5% to 10% of pediatric and up to 30% of adult T-ALL cases1–4. In addition, 
TLX3, a highly related TLX family member, is overexpressed as result of the t(5;14)
(q35;q32) translocation in about 25% of pediatric TALLs and in 5% of adult T-ALL cases5. 
TLX1 expression defines a distinct molecular group of T-ALL characterized by a 
differentiation block at the early cortical stage of thymocyte development2 and favorable 
prognosis1,2,6. Moreover, TLX1 and TLX3 leukemias seem to constitute a distinct 
oncogenic group with specific genetic alterations rarely found in non-TLX induced T-ALLs 
including the rearrangement of the NUP214-ABL1 oncogene7 and mutations in the WT18 
and PHF69 tumor suppressor genes. However, little is known about the specific 
mechanisms that mediate T-cell transformation downstream of TLX1. To address this 
question we have used an integrative genomic approach to characterize the transcriptional 
programs and oncogenic pathways active in human and mouse TLX1-induced leukemia.
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T-ALL development in TLX1 transgenic mice
In order to investigate the mechanisms of T-cell transformation driven by TLX1, we 
generated p56Lck-TLX1 transgenic mice in which the Lck proximal promoter drives 
expression of TLX1 in T-cell progenitors10,11. TLX1 transgenic mice from three founder 
lines showed accelerated mortality due to the development of lymphoid tumors with a 
median latency of 27, 32 or 46 weeks, respectively (P<0.0001) (Fig. 1a). Tumor-bearing 
mice showed enlarged thymi populated by immature lymphoblasts and leukemic infiltration 
of bone marrow and peripheral organs including lymph nodes, spleen, liver and kidneys 
(Fig. 1b). Overall, 92% of TLX1 transgenic animals developed tumors at 52 weeks. TLX1-
induced leukemias showed high levels of TLX1 protein (Fig. 1c–d) and expression of CD3 
indicative of a T-cell phenotype (Fig. 1e). Moreover, flow cytometry analysis demonstrated 
the expression of CD4 and CD8 in most tumors (Fig. 1f–g). In addition, this analysis 
revealed significant heterogeneity in these leukemias with 53% of the tumors showing two 
or more immunophenotypically different cell populations (Fig. 1f). Finally, TLX1-induced 
tumors showed clonal expression of a single TCRB chain in 4/5 tumors examined and only 2 
TCRB chains in the remaining sample (Fig. 1h), indicating that despite their heterogeneous 
immunophenotypes these are monoclonal T-cell tumors.
Mouse and human TLX-induced T-ALLs have a common expression signature
To address the transcriptional programs activated in mouse TLX1 leukemias, we analyzed 
the expression profiles of mouse tumors from TLX1 transgenics (n=6) and of T-ALLs 
generated by retroviral insertional mutagenesis or arising in the context of different T-ALL 
transgenic and knockout models including Tal1, Lmo2 and Olig2/Bhlhb1 transgenics and 
Tcf3/E2A, Trp53 and Pten knockouts (n=49) (Supplementary Table 1). Significant 
differentially expressed genes were calculated by Comparative Marker Selection 
Genepattern tool12 using t-test statistical test and non-parametric P value calculation (1,000 
random permutations). This analysis revealed that TLX1 tumors are characterized by a 
distinct gene expression signature with upregulation of 114 genes and downregulation of 
377 transcripts (Fold change >2, P <0.005) (Fig. 2a; Supplementary Table 2). Moreover, 
Gene Set Enrichment Analysis (GSEA) of human T-ALL (n=82) using these mouse TLX1-
signature genes showed significant enrichment in human TLX1 and TLX3 tumors (P<0.001)
(Fig. 2b; Supplementary Table 3), highlighting the relevance of our mouse model for the 
analysis of TLX-induced transformation.
TLX1 expression blocks T-cell development and induces apoptosis
Next, we decided to explore the effects and mechanistic role of TLX1-expression in T-cell 
progenitors in young TLX1 transgenic mice prior to the development of T-ALL. Analysis of 
TLX1-transgenic mice at 3 and 6 weeks of age showed a drastic reduction in thymic size 
and cellularity compared with littermate controls (Fig. 3a), but no clear defects in cell 
proliferation (Fig. 3b). Flow cytometry analysis of thymocyte differentiation markers in 
TLX1 transgenic animals and littermate controls showed a defect in T-cell development with 
arrest at the double negative 2 (DN2) stage of thymocyte differentiation (Fig. 3c), which was 
accompanied by a marked increase in apoptosis (Fig. 3d,e). Consistent with these results, 
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transgenic expression of BCL2 in Lck-TLX1 VavP-BCL2 double transgenic mice abrogated 
apoptosis (Fig. 3f) and rescued the defect in thymus size (Fig. 3g) and cellularity (Fig. 3h) 
observed in preleukemic TLX1-transgenic mice.
Secondary mutations in the pathogenesis of TLX1-induced T-ALL
The prolonged latency in the development of T-ALL in TLX1 transgenic mice and the clonal 
nature of these tumors prompted us to investigate the presence of cooperating mutations 
involved in the pathogenesis of TLX1-induced leukemias. Activating mutations in NOTCH1 
are present in over 50% of human T-ALLs13,14. Similarly, prototypical mutations in 
Notch1 were present in 3/25 (12%) TLX1-induced mouse tumors (Supplementary Table 4). 
Moreover, array Comparative Genomic Hybridization (aCGH) analysis revealed the 
presence of recurrent numerical and structural chromosomal alterations in these tumors (Fig. 
4a, Supplementary Fig. 1). Thus, focal homozygous deletions affecting the Pten tumor 
suppressor gene were present in 4/15 (27%) samples (Fig. 4a, Supplementary Fig. 1, 
Supplementary Table 5). In addition, immunohistochemical analysis of Pten showed loss of 
Pten protein expression in 11/24 (42%) tumors (Supplementary Fig. 1). Notably, PTEN 
deletions, mutations and loss of PTEN protein expression have been reported in 20% of 
human T-ALLs15,16. Chromosomal deletions involving Trp53 and Ikzf1, which are 
sporadically mutated and deleted in human T-ALLs17,18, were detected in one tumor each 
(Fig. 4a, Supplementary Fig.1, Supplementary Table 5). In addition three mouse TLX1 T-
ALL samples harbored heterozygous deletions in chromosome 12 with a common deleted 
region containing only the Bcl11b gene (Fig. 4a–c, Supplementary Table 5). Moreover, 
DNA sequence analysis of Bcl11b showed the presence of Bcl11b mutations in 4/15 (27%) 
mouse TLX1-induced T-ALLs (Fig. 4d–e, Supplementary Table 6), which together with the 
3 Bcl11b deletions identified in our aCGH analysis brings the prevalence of Bcl11b 
alterations in mouse TLX1-induced tumors to 7/15 (47%). Notably, mutation analysis of 
Bcl11b in T-ALL tumors occurring in Pten knockout animals (n=6), Trp53 knockout mice 
(n=2), Ctnnb1 transgenic animals (n=4) or induced by retroviral insertional mutagenesis 
(n=9) failed to detect any Bcl11b mutations in these non-TLX1 transgenic tumors (Fisher’s 
exact test P <0.001).
Recurrent deletions and mutations in BCL11B in human T-ALL
Bcl11b encodes a zinc finger transcription factor with a critical role in the differentiation and 
survival of T-cell progenitors in the thymus19,20. Given the similarities between our mouse 
model of TLX1-induced leukemia and human T-ALL, we hypothesized that BCL11B 
alterations could also be implicated in the pathogenesis of human T-ALL. Most notably, 
aCGH analysis of human T-ALL samples showed the presence of focal heterozygous 
deletions encompassing the BCL11B locus in 2/69 (3%) T-ALL cases (Fig. 5a). In addition, 
mutation analysis of BCL11B in human T-ALL demonstrated the presence of truncating 
frameshift mutations and missense point mutations in 9/71 (13%) cases analyzed (Fig. 5b). 
Interestingly, all 6 BCL11B missense mutations involved zinc finger domains (Fig. 5b). One 
sample showed compound heterozygous BCL11B mutations while the remaining 5 cases 
harbored heterozygous BCL11B lesions (Supplementary Table 7). Notably, sequence 
analysis of samples obtained at the time of clinical remission demonstrated the somatic 
origin of BCL11B mutations in all 6 cases with available material (Fig. 5c). Finally, 
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expression analysis of TLX1 or TLX3 in 8 T-ALLs harboring mutations or deletions in 
BCL11B with RNA available showed aberrant expression of these transcription factor 
oncogenes in 5/8 (63%) [TLX1 (4/8); TLX3 (1/8)] of these samples (Supplementary Table 7). 
Altogether, these results identify BCL11B as a tumor suppressor gene recurrently deleted 
and mutated in human T-ALL.
Interaction between BCL11B and TLX1 in T-cell transformation
The identification of a high prevalence of Bcl11b mutations and deletions in TLX1-induced 
tumors suggest a specific genetic interaction between these two genes in T-cell 
transformation. To test if BCL11B could be a direct transcriptional target of TLX1 in T-
ALL, we analyzed the binding of TLX1 to the BCL11B promoter via chromatin 
immunoprecipitation analysis in ALL-SIL, a T-ALL cell line expressing high levels of TLX1 
as result of the t(10;14)(q24;q11) translocation21. This analysis revealed that indeed TLX1 
binds to the BCL11B promoter (Fig. 5d). Moreover, siRNA knockdown of TLX1 in this cell 
line resulted in transcriptional upregulation of BCL11B (Fig. 5e), indicating that BCL11B is 
a direct transcriptional target downregulated by TLX1 in T-ALL.
TLX1 T-ALLs are aneuploid and have a defective mitotic checkpoint
In addition to identifying focal areas of amplification and deletion, our aCGH analysis of 
mouse TLX1 tumors showed gains and losses of whole chromosomes in most samples 
analyzed, suggesting a high prevalence of numerical chromosomal abnormalities in these 
leukemias (Fig. 4a, Supplementary Table 8). Spectral karyotyping (SKY) analysis confirmed 
these results and showed the presence of trisomy 15 in 3/4 TLX1 tumor samples analyzed 
(Fig. 6a, Supplementary Table 8). Overall, 78% (14/18) of TLX1-induced leukemias showed 
chromosomal gains and losses, with 67% (12/18) harboring trisomy 15 (alone or in 
combination with trisomy 17, gain of chromosome Y, monosomy X or hyperdiploidy) (Fig. 
6b, Supplementary Table 8). Previous in vitro studies had associated TLX1 with alterations 
in the G2/M cell cycle checkpoint22 and forced expression of TLX1 can induce aneuploidy 
in B-cells after disruption of the mitotic spindle23. To test the function of the mitotic 
checkpoint in our TLX1-induced leukemias we treated TLX1-T-ALL lymphoblasts with 
taxol, which impairs microtubule remodeling. This analysis revealed that TLX1 mouse T-
ALL lymphoblasts fail to arrest in mitosis following disruption of the mitotic spindle (Fig. 
6c). In contrast, tumors induced by the TAL1, TAL1 plus LMO1, TAL1 plus LMO2 and 
NUP214-ABL1 T-ALL oncogenes showed a marked accumulation of cells in mitosis after 
taxol treatment (Fig. 6c, Supplementary Fig. 2). Similar results were obtained using 
nocodazole, which disrupts tubulin polymerization (Fig. 6c), and BrdU incorporation 
analysis verified that TLX1 mouse tumors proliferate and fail to arrest in M phase following 
disruption of the mitotic spindle (Supplementary Fig.3).
TLX1 directly downregulates mitotic genes in T-cell transformation
The acquisition of chromosomal instability may represent an early event in the pathogenesis 
of cancer24. To investigate the specific mechanisms involved in the earliest stages of TLX1-
induced transformation, we performed microarray gene expression analysis of sorted 
preleukemic DN2 cells from 3 week old mice. Significant differentially expressed genes 
De Keersmaecker et al. Page 5













were calculated by Comparative Marker Selection Genepattern tool12 as described above. 
This analysis revealed marked differences in gene expression in TLX1 transgenic 
thymocytes and DN2 cells from normal littermate controls with 175 genes upregulated and 
138 genes downregulated in TLX1-expressing cells (Fold change > 1.5, P<0.005) 
(Supplementary Table 9). Next, and to specifically address the role of direct TLX1 target 
genes in T-cell transformation, we performed ChIP-chip analysis of TLX1 in ALL-SIL cells. 
In these experiments, TLX1 chromatin immunoprecipitates were hybridized to human 
proximal promoter arrays and analyzed using ChIP-chip Significance Analysis (CSA) to 
identify high confidence TLX1 direct target genes25. This analysis identified 5,549 
promoters bound by TLX1 with a significance cutoff of P<0.0001 (Supplementary Table 
10). Integration of these ChIP-chip results with the gene expression signature associated 
with aberrant expression of TLX1 in T-cell progenitors revealed a marked enrichment of 
TLX1 direct target genes involved in mitosis (P <0.001) (Supplementary Table 11) 
downregulated in TLX1-preleukemic cells (Fig.6d and Supplementary Fig. 4). Notably, 
these included CHEK1, a key regulator of the mitotic spindle checkpoint and one of the 
genes most consistently downregulated in both mouse and human TLX-induced leukemias 
(Supplementary Tables 2 and 3). Consistent with these results, TLX1-knockdown in ALL-
SIL cells resulted in transcriptional upregulation of CHEK1 (Fig.6g) and pharmacologic 
inhibition of CHEK1 in human TALL cell lines abrogated the activation of the mitotic 
checkpoint upon treatment with taxol (Supplementary Fig. 5). These results suggest a 
mechanistic role of TLX1 in the control of cell cycle checkpoint genes at the earliest stages 
of T-cell transformation.
To test if TLX1 expression can induce a defective mitotic checkpoint phenotype in 
preleukemic cells we isolated viable thymocytes from TLX1-BCL2 double transgenic mice 
and compared them with cells obtained from BCL2 transgenic controls. This experiment 
showed a marked defect in the activation of the mitotic checkpoint after taxol treatment in 
TLX1-BCL2 preleukemic cells compared with BCL2 controls (Fig. 6h). The polyclonal/non 
transformed nature of TLX1-BCL2 preleukemic cells was verified by RT-PCR analysis of 
TCRB expression (Supplementary Fig. 6). Overall, these results demonstrate that the 
impaired control of the mitotic checkpoint in TLX1-transgenic mice is an early event in 
tumor formation that precedes clonal selection in T-cell transformation.
Chromosomal alterations in human TLX-induced leukemias
Overall the results described above support a direct mechanistic role for TLX1 in the 
induction of chromosomal missegregation suggesting that similar mechanisms may operate 
in the pathogenesis of human leukemias. Most notably, and consistent with this thesis, the 
TLX1-positive ALL-SIL cell line showed a selective defect in the mitotic checkpoint 
(Supplementary Fig. 2). In addition, karyotype analysis of a series of 57 well characterized 
pediatric T-ALLs2 demonstrated a higher frequency of aneuploid karyotypes (8/13, 62%) in 
TLX1 and TLX3 positive human T-cell tumors compared with other genetic subgroups of T-
ALL (5/44, 11%) (Fisher’s exact test P <0.001) (Supplementary Table 12). Moreover, 
analysis of an independent series of 229 T-ALLs showed a marked predominance of 
numerical chromosomal abnormalities in TLX1 and TLX3 positive T-ALLs (aneuploidy/
pseudodiploid karyotype ratios: 6/1 for TLX1 tumors; 10/10 for TLX3 leukemias and 24/63 
De Keersmaecker et al. Page 6













for non-TLX T-ALLs; Fisher’s exact test P <0.004 for TLX1 vs. non-TLX; P <0.05 for TLX3 
vs. non-TLX and P <0.003 for TLX1/TLX3 vs. non-TLX) (Supplementary Table 13).
Discussion
TLX1 plays a central role in the pathogenesis of T-ALL. However the elucidation of the 
specific mechanisms that mediate T-cell transformation downstream of TLX1 has been 
hampered by the lack of an animal model of TLX1-induced T-ALL and by the lack of 
understanding of the direct transcriptional targets controlled by TLX1 in human leukemia. 
Here we demonstrate that TLX1 transgenic mice develop clonal immature T-cell tumors 
highly related to human TLX1 and TLX3 TALLs in their clinical presentation and gene 
expression signatures. The extended latency in the development of leukemia in this model 
and the clonal nature of TLX1-induced tumors suggest that TLX1 overexpression in the 
thymus is not sufficient for malignant transformation of T-cell progenitor cells. This thesis is 
further supported by the identification of recurrent cooperating mutations and chromosomal 
abnormalities in mouse TLX1-induced leukemias. Most notably, TLX1-induced tumors 
harbored recurrent alterations in oncogenes (Notch1) and tumor suppressor genes (Pten, 
Cdkn2a) frequently mutated in human T-ALL13–15,26. In addition this analysis revealed 
the presence of recurrent mutations and deletions centered on the Bcl11b locus in 47% of 
mouse TLX1-induced tumors analyzed. Based on these results, we hypothesized that 
BCL11B could play a tumor suppressor role in human leukemia and identified recurrent 
deletions and mutations in this gene in 16% of human TALLs. Notably, most BCL11B 
alterations found in mouse TLX1-induced tumors and in human T-ALLs were heterozygous 
and loss of one copy of Bcl11b in mice accelerates the development of thymic lymphomas 
after γ-irradiation or in Trp53 heterozygous mice without loss of the wild type Bcl11b 
allele27. Finally, ChIP and expression analysis demonstrated that BCL11B is a direct 
transcriptional target downregulated by TLX1 in T-ALL. The model that emerges from 
these results is that aberrant expression of TLX1 partially downregulates the BCL11B tumor 
suppressor gene during T-cell transformation and that this negative transcriptional 
regulatory axis is fixed and reinforced by secondary genetic alterations in the BCL11B locus 
acquired during tumor progression. Strikingly, PHF6 and WT1, two additional tumor 
suppressor genes frequently mutated in TLX1-induced T-ALL are also among the TLX1 
targets identified in our ChIP-on-chip analysis (Supplementary Table 10), suggesting that 
this model could also apply to these TLX1-target tumor suppressor genes.
Perhaps the most striking finding in TLX1-induced leukemias was the presence of a very 
high incidence of numerical chromosomal alterations in these tumors, indicating that 
alterations in the mitotic machinery could play an important role in TLX1-induced 
transformation. Consistent with this model, our results demonstrate that TLX1-induced T-
ALLs have a defective mitotic checkpoint and fail to arrest in mitosis upon treatment with 
taxol or nocodazole. Moreover, this mitotic checkpoint defect is readily present in 
preleukemic thymocytes from TLX1 transgenic mice, suggesting that aneuploidy represents 
a direct effect of TLX1 overexpression and an early event in the genesis of mouse TLX1-
induced tumors.
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Mechanistically, analysis of TLX1 direct target genes in the context of TLX1 preleukemic 
thymocytes revealed that multiple TLX1 direct target genes involved in mitosis and 
chromosomal segregation are downregulated in T-cell progenitor cells isolated from TLX1 
transgenic mice. Among these, CHEK1, a critical checkpoint regulator, is downregulated in 
mouse and human TLX-induced leukemias and could have a particularly prominent role in 
the loss of the mitotic checkpoint downstream of TLX1. However, it would be deceiving to 
attribute the induction of aneuploidy by TLX1 to the dysregulation of a single gene, as 
multiple transcripts with prominent roles in mitosis seem to be controlled by TLX1 in T-
cells. In addition, a transcription independent effect of TLX1 in the control of cell cycle via 
interaction with the PP2A phosphatase has been proposed22.
Overall, our results mechanistically link the aberrant expression of TLX1 with the 
development of chromosomal instability at the earliest stages of T-cell transformation and 
illustrate the power of integrative genomic analyses of mouse and human tumors to elucidate 




The human TLX1 cDNA was amplified by PCR using BamHI restriction site containing 
primers and cDNA of the human T-cell leukemia cell line ALL-SIL as template and was 
cloned in the pUC1017 vector, downstream of the mouse T-cell specific p56Lck proximal 
promoter. C57BL/6J VavP-Bcl2 transgenic mice have been described before 28,29. Animal 
experiments were performed under the supervision of the Columbia University Medical 
Center IACUC.
Gene expression profiling of mouse tumors
We profiled a cohort of 6 TLX1 transgenic-derived TALLs and additional 49 T-cell 
lymphoblastic tumors from different genetic models of T-ALL (see Supplementary Table 1 
for details on the genetic background of tumors analyzed). Gene-expression profiling was 
performed using Affymetrix Mouse Genome 430A 2.0 Array following standard procedures. 
Raw data is available in GEO (accession number GSE19499). Array normalization was 
performed by DNA-Chip-Analyzer (dChip)30. Following interarray normalization we 
preprocessed and analyzed the microarray data for differential expression using the 
Genepattern platform for microarray analysis31.
Gene expression profiling human T-ALL
Affymetrix gene expression data from pediatric T-ALL samples has been reported before 
(GEO accession # GSE10609)32. This series encompasses 7 TLX1 positive cases, 23 TLX3 
positive samples and 53 other T-ALLs including 33 tumors with aberrant expression of 
TAL1 and LMO2. Tumors with high levels of expression of HOXA9 constitute a 
heterogeneous molecular group resulting from translocations involving the HOXA loci, 
aberrant expression of CALM-AF10, SET-NUP214 and MLL fusion oncogenes and were a 
priory excluded from this series. Enrichment of the TLX1 direct target genes identified by 
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ChIP-chip (P <10−4) in the TLX1 and TLX3 class signature was analyzed by GSEA using the 
signal-to-noise metric and a 1,000 permutations of the class labels.
Gene expression profiling of normal and TLX1 transgenic thymocytes
We isolated single cell suspensions of thymi from 3 week old wild type and TLX1 transgenic 
littermates and isolated CD4− CD8− CD44+CD25+ cells on a FACS ARIA Sorter (Beckton 
Dickinson). We collected cells in RLT buffer (Qiagen) and extracted RNA with the RNeasy 
mini kit (Qiagen). We verified RNA quantity and quality on a Nanodrop spectrophotometer 
and an Agilent Bioanalyzer 2100, respectively. We used the Ovation RNA Amplification 
System V2 (NuGEN) to generate amplified cDNA, which was subsequently fragmented and 
labeled with the FL-Ovation cDNA Biotin Module V2 (NuGEN) and hybridized on Mouse 
Genome 430 2.0 Arrays (Affymetrix).
Array normalization and data analysis was performed as described above. Significant 
differentially expressed genes were calculated by the Comparative Marker Selection 
Genepattern tool using t-test statistical test with an asymptotic P value and zero 
permutations.
For enrichment analysis of mitotic genes controlled by TLX1 in preleukemic cells, we first 
identified 155 mitotic regulators (GO:0000278~mitotic cell cycle) within the top 5,549 
TLX1 targets identified by ChIP-chip (P< 0.0001) using the DAVID (http://
david.abcc.ncifcrf.gov/) Functional Annotation tool, and used this geneset to run GSEA in 
TLX1 transgenic versus wild type DN2 cells test using the signal-to-noise metric and 1,000 
permutations of the gene list.
Array comparative genomic hybridization (aCGH)
We performed aCGH analysis of mouse tumors using the Mouse Genome CGH 244A 
platform (Agilent Technologies) according to the instructions of the manufacturer. To 
analyze these data we used DNA Analytics 4.0 software (Agilent Technologies). For Array-
CGH analysis of human T-ALLs we used SurePrint G3 Human CGH 1x1M Oligo 
Microarrays (Agilent Technologies). We analyzed human array CGH data with the Genomic 
Workbench 5.0.14 software (Agilent Technologies).
Mitotic checkpoint analysis
Integrity of the mitotic checkpoint was tested by flow cytometry analysis of cell cycle in 
cells treated with 1 μM taxol (Sigma) (human cell lines), 0.1 μM taxol (mouse cell lines), 
100 ng ml−1 nocodazole (Sigma) or vehicle for 24 hours. For analysis of the mitotic 
checkpoint in pre-leukemic mouse cells, thymocytes from 3 week old VavP-Bcl2 and VavP-
Bcl2/TLX1 transgenic littermates were cultured on OP9-DL1 cells for 24 hours followed by 
taxol treatment and cell cycle analysis as described above.
TLX1 ChIP-chip analysis
We performed ChIP-chip analysis of TLX1 direct target genes in the ALL-SIL T-ALL cell 
line using a rabbit polyclonal TLX1-specific antibody (C-18, sc-880) (Santa Cruz 
Biotechnology) using Agilent Human Proximal Promoter Microarrays (244K features/array) 
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as previously described33. We identified TLX1 direct targets via ChIP-chip Significance 
Analysis (CSA) as described before25.
Quantitative ChIP Analysis
Relative real-time PCR quantitation of promoter sequences was normalized to β-actin levels 
in chromatin immunoprecipitates performed with a TLX1-specific antibody (C-18 rabbit 
polyclonal antibody (sc-880), Santa Cruz Biotechnology), or an IgG antibody. Primer 
sequences are listed in Supplementary Table 15.
siRNA knockdown
In TLX1 siRNA knockdown experiments we electroporated ALL-SIL cells (275V, 1,000 
μF) using a Genepulser MXcell electroporator (Biorad) with 200 nM of Silencer Select 
Negative Control #1 siRNA (Ambion, cat #4390844) or TLX1 siRNA1 (5’-
GAUGGAGAGUAACCGCAGAtt-3’). Knockdown efficiency was measured by 
quantitative RT-PCR and Western blot.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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TLX1-induced T-cell leukemias in mice. (a) Kaplan-Meier survival curves of p56Lck-TLX1 
transgenic mice and littermate controls from three independent founder lines. Accelerated 
mortality in TLX1 transgenic mice was associated with the development of immature T-cell 
tumors. (b) Infiltration of thymus, spleen, bone marrow and liver by immature lymphoblasts. 
(c) Western blot analysis of TLX1 expression in mouse T-cell tumors. (d-e) 
Immunohistochemical analysis of TLX1 (d) and CD3 expression in mouse TLX1-induced T-
ALL cells (e). Scale bar 100 μm. (f,g) Immunophenotype distribution (f) and representative 
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flow cytometry plots (g) showing heterogeneous expression of CD4 and CD8 in TLX1-
induced leukemias. DN, double negative; DP, double positive; SP, single positive. (h) 
Clonality analysis by expression of TCRB chains in TLX1-induced tumors. Polyclonal 
expression of TCRB in normal thymocytes is shown as control (upper row).
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Molecular signatures associated with TLX1-induced transformation. (a) Heat map diagram 
of the 50 top ranking differentially expressed genes by t-test in mouse TLX1-induced 
leukemias. (b) GSEA analysis of differentially expressed genes associated with TLX1-
induced transformation in mice demonstrates enrichment of this signature in human TLX1/
TLX3 expressing T-ALLs. Gene set: Human orthologs of mouse TLX1 signature genes. Data 
set: TLX1/TLX3 positive vs. TLX1/TLX3 negative human leukemias. Enrichment plots (left) 
and heat map representations of the 50 top ranking genes in the leading edge (right) are 
shown. Genes in heat maps are shown in rows, each individual sample is shown in one 
column. The scale bar shows color coded differential expression from the mean in standard 
deviation units with red indicating higher levels and blue lower levels of expression.
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Fig 3. Developmental defects in thymocyte development in TLX1-transgenic mice
(a) Preleukemic TLX1 transgenic mice at 6 weeks of age showed decreased thymus weight 
and cellularity compared with littermate controls. Scale bar 10 mm. (b) Cell cycle analysis 
of control and preleukemic TLX1-transgenic thymocytes via PI staining of DNA content 
analyzed by flow cytometry. (c) Flow cytometry analysis of T-cell development in 
preleukemic TLX1-transgenic animals. Accumulation of CD44+CD25+ cells shows a 
differentiation block at the DN2 stage of thymocyte development. (d) Apoptosis analysis of 
control and TLX1-transgenic preleukemic thymocytes via annexinV/PI staining. (e) TUNEL 
staining on thymus tissue sections. Scale bars represent 100 μm. (f-h) Transgenic expression 
of BCL2 inhibits apoptosis (f) and reverses thymic weight (g) and cellularity (h) in 
preleukemic TLX1 +BCL2 double transgenic mice.
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Numerical and structural chromosomal alterations in TLX1-induced mouse T-ALLs. (a) 
Mouse chromosomal ideogram showing the areas of genetic gain and loss identified by 
aCGH in TLX1 thymic tumors. Red bars represent areas of gain. Green bars represent areas 
of copy number loss. (b) Schematic representation of the chromosome 12q commonly 
deleted region encompassing the Bcl11b locus in mouse TLX1-induced tumors. (c) Array 
CGH plot showing a focal deletion of the Bcl11b gene in a mouse TLX1-induced T-ALL. (d) 
Schematic representation of Bcl11b mutations identified in mouse TLX1-induced T-ALLs. 
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(e) DNA sequence chromatograms corresponding to Bcl11b mutations identified in mouse 
TLX1-induced T-ALLs.
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BCL11B is a TLX1 target gene mutated in human T-ALL. (a) Array CGH plots showing 
focal deletions in chromosomal band 14q32.2 encompassing the BCL11B locus in human T-
ALL. (b) Schematic representation of BCL11B mutations identified in human T-ALL. (c) 
DNA sequence analysis of BCL11B in diagnostic and remission T-ALL samples. (d) ChIP 
analysis of TLX1 binding to BCL11B regulatory sequences in ALL-SIL cells. (e) Western 
blot analysis of TLX1 and RT-PCR analysis of BCL11B expression in ALL-SIL cells 
electroporated with control or TLX1 siRNAs.
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Numerical chromosomal alterations and defects in the mitotic checkpoint in TLX-transgenic 
mice. (a) SKY analysis of a mouse TLX1-induced tumor with trisomy 15. (b) Distribution of 
numerical chromosomal aberrations found by SKY and aCGH analysis in mouse TLX1-
induced leukemias. (c) Cell cycle analysis of vehicle only, taxol and nocodazole treated 
mouse T-ALLs showing defective activation of the mitotic checkpoint in mouse TLX1-
positive leukemia cells. (d) GSEA analysis of mitotic regulators identified as TLX1 direct 
target genes by ChIP-chip in sorted thymocytes (DN2 cells) from wild type and preleukemic 
TLX1 transgenic mice. Gene set: TLX1 direct targets in mitotic cell cycle (GO:0000278). 
Data set: TLX1 transgenic preleukemic cells vs. wild type. The enrichment plot (left) and 
heat map representation of the top 25 mitotic genes in the rank of transcripts differentially 
expressed in TLX1-preleukemic cells (right) are shown. The scale bar at the bottom shows 
color coded differential expression from the mean in standard deviation units with red 
indicating higher levels and blue lower levels of expression. (e) RT-PCR analysis of Chek1 
expression in thymocytes isolated from wild type or TLX1-transgenic mice. (f) ChIP analysis 
of TLX1 binding to CHEK1 regulatory sequences in ALL-SIL cells. (g) RT-PCR analysis of 
TLX1 and CHEK1 expression in ALL-SIL cells electroporated with control or TLX1 
siRNAs. (h) Cell cycle analysis of vehicle only and taxol treated mouse thymocytes from 
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BCL2 transgenic and TLX1-BCL2 double transgenic mice showing defective activation of 
the mitotic checkpoint in mouse TLX1-BCL2-expressing preleukemic cells.
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